Complicated Urinary Tract Infection market size is projected to grow at a CAGR of 5.7% by 2034

The Complicated Urinary Tract Infections market size across the 7MM was valued at approximately USD 1,375 million in 2025 and is projected to reach around USD 2,259 million by 2034, growing at a CAGR of 5.7% during the forecast period (2025-2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Complicated Urinary Tract Infection landscape.

In 2024, the United States reported approximately 3.56 million diagnosed cases of complicated urinary tract infections. Age-specific estimates indicated around 40,000 cases among individuals aged 0–17 years, 268,000 in the 18–44 age group, 247,000 in those aged 45–54, 511,500 among individuals aged 55–64, 1,759,500 in the 65–84 group, and 732,000 cases among people aged 85 years and older.

In 2024, females accounted for nearly 70% of complicated urinary tract infection (cUTI) cases in the United States, while males represented around 30%. Across the 7MM, there were approximately 10,746,500 treated cases of cUTI, including about 8,266,500 first-line cases and roughly 2,480,000 recurrent cases.

DelveInsight’s report “Complicated Urinary Tract Infection Market Insights, Epidemiology, and Market Forecast-2034” provides a comprehensive analysis of the Complicated Urinary Tract Infection landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.
 
To Know in detail about the Complicated Urinary Tract Infection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Complicated Urinary Tract Infection Market Forecast

Some of the key facts of the Complicated Urinary Tract Infection Market Report:

• Key Complicated Urinary Tract Infection Companies: Merck Sharp & Dohme, AbbVie, Pfizer, Allecra Therapeutics, Wockhardt, Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, GlaxoSmithKline, Locus Biosciences, Forest Laboratories, Allecra, Xiangbei Welman Pharmaceutical, Bayer, Mepha Ltd., Pinnacle Pharmaceuticals, Inc., Bionorica SE, and others
• Key Complicated Urinary Tract Infection Therapies: RECARBRIO (imipenem, cilastatin, and relebactam), AVYCAZ (ceftazidime/avibactam), enmetazobactam, zidebactam (WCK-5222), Tebipenem Pivoxil Hydrobromide (SPR994), Cefepime/zidebactam (WCK-5222), Cefepime/taniborbactam, Gepotidacin, LBP-EC01, Ceftaroline fosamil and NXL104 (q8h), cefepime/AAI101 combination, Piperacillin Sodium and Sulbactam Sodium, Cipro XR (Ciprofloxacin, BAYQ3939), Nitrofurantoin, PP4001, Canephron® N, and others
• The Complicated Urinary Tract Infection market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Complicated Urinary Tract Infection pipeline products will significantly revolutionize the Complicated Urinary Tract Infection market dynamics.

Complicated Urinary Tract Infection Overview

Complicated Urinary Tract Infection (cUTI) refers to a urinary tract infection that occurs in individuals with structural or functional abnormalities of the urinary tract, or in those with underlying health conditions that increase the risk of treatment failure or recurrence. These infections often involve the kidneys, ureters, or bladder and are typically caused by multidrug-resistant bacteria, such as Escherichia coli and Klebsiella pneumoniae.
Common predisposing factors include urinary catheters, kidney stones, diabetes, pregnancy, or weakened immune systems. Unlike uncomplicated UTIs, cUTIs require longer and more aggressive treatment, often with broad-spectrum or intravenous antibiotics, to prevent severe complications like sepsis or kidney damage.
 
Get a Free sample for the Complicated Urinary Tract Infection Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market

Key Trends in Complicated Urinary Tract Infection Therapeutics Market:

• Rising Prevalence of Drug-Resistant Pathogens: Increasing cases of multidrug-resistant Escherichia coli and Klebsiella pneumoniae are driving demand for novel antibiotic classes and combination therapies.
• Shift Toward Novel Mechanisms of Action: Companies are focusing on developing therapies such as siderophore cephalosporins (e.g., cefiderocol) and β-lactamase inhibitors to combat resistance and improve treatment outcomes.
• Increased Adoption of Outpatient Parenteral Antimicrobial Therapy (OPAT): Growing preference for OPAT enables effective treatment outside hospital settings, reducing healthcare costs and hospital stays.
• Pipeline Expansion with Non-Antibiotic Approaches: Research is accelerating into alternative strategies like bacteriophage therapy, antimicrobial peptides, and immune-modulating agents to address antibiotic resistance.
• Regulatory Support and Fast-Track Approvals: Global regulatory agencies, including the FDA and EMA, are offering incentives such as QIDP (Qualified Infectious Disease Product) designations to encourage antibiotic innovation.
• Strategic Collaborations and Partnerships: Pharma and biotech companies are increasingly collaborating with academic institutions and government programs to enhance R&D capabilities and accelerate drug commercialization.
• Growing Emphasis on Diagnostic Advancements: Rapid diagnostic tools for pathogen identification and resistance profiling are improving personalized treatment selection and clinical decision-making in cUTI management.

Complicated Urinary Tract Infection Epidemiology

The cUTI epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Complicated Urinary Tract Infection Epidemiology Segmentation:

The Complicated Urinary Tract Infection market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed Incident Cases of cUTI in the 7MM
• Total Diagnosed Incident Cases of cUTI Progressed From uUTI in the 7MM
• Total Age-specific Cases of cUTI in the 7MM
• Total Pathogen-specific Cases of cUTI in the 7MM
• Total Treated Cases of cUTI in the 7MM

Download the report to understand which factors are driving Complicated Urinary Tract Infection epidemiology trends @ Complicated Urinary Tract Infection Epidemiology Forecast

Recent Developments In The Complicated Urinary Tract Infection Treatment Landscape:

• In October 2025, GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) have announced the complete results from the pivotal Phase III PIVOT-PO trial assessing tebipenem HBr, an investigational oral therapy for complicated urinary tract infections (cUTIs), including pyelonephritis (NCT06059846). The findings were presented on October 20, 2025, during a late-breaking oral abstract session at ID Week 2025 in Atlanta, USA.
• In May 2025, Spero Therapeutics and GSK announced that their Phase 3 clinical trial evaluating the investigational oral antibiotic tebipenem hydrobromide (HBr) for complicated urinary tract infections (cUTIs) was halted early due to positive efficacy results. The PIVOT-PO trial was discontinued following a recommendation from the Independent Data Monitoring Committee (IDMC), which determined that the study met its primary endpoint in patients with cUTIs, including pyelonephritis. The IDMC also reported no new safety concerns, with diarrhea and headache remaining the most common side effects, consistent with findings from earlier studies.
• In March 2025, Meiji Seika Pharma announced that it had achieved positive results in a global Phase III clinical trial of OP0595, a novel ß-lactamase inhibitor developed to combat AMR. The trial targeted patients with cUTI or acute, uncomplicated pyelonephritis.
• In January 2025, Wockhardt announced that ZAYNICH demonstrated unprecedented efficacy in a global, pivotal Phase III study for cUTI, achieving a clinical cure rate of 96.8% and successfully meeting superiority criteria for registration.

Complicated Urinary Tract Infection Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Complicated Urinary Tract Infection market or expected to get launched during the study period. The analysis covers Complicated Urinary Tract Infection market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Complicated Urinary Tract Infection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Complicated Urinary Tract Infection Therapies and Key Companies

• RECARBRIO (imipenem, cilastatin, and relebactam): Merck Sharp & Dohme
• AVYCAZ (ceftazidime/avibactam): AbbVie/Pfizer
• enmetazobactam: Allecra Therapeutics
• zidebactam (WCK-5222): Wockhardt
• Gepotidacin: GlaxoSmithKline
• LBP-EC01: Locus Biosciences
• Ceftaroline fosamil and NXL104 (q8h): Forest Laboratories
• cefepime/AAI101 combination: Allecra
• Piperacillin Sodium and Sulbactam Sodium: Xiangbei Welman Pharmaceutical
• Cipro XR (Ciprofloxacin, BAYQ3939): Bayer
• Nitrofurantoin: Mepha Ltd.
• PP4001: Pinnacle Pharmaceuticals, Inc.
• Canephron® N: Bionorica SE

Discover more about therapies set to grab major Complicated Urinary Tract Infection market share @ Complicated Urinary Tract Infection Treatment Landscape

Complicated Urinary Tract Infection Market Drivers

• Rising Incidence of cUTI Cases: Increasing prevalence of diabetes, catheter use, and urinary tract abnormalities is leading to a higher number of complicated infections globally.
• Growing Antimicrobial Resistance (AMR): The rise of multidrug-resistant pathogens is driving the need for advanced and more effective therapeutic options.
• Advancements in Drug Development: Continuous R&D efforts are leading to the introduction of novel antibiotics and β-lactamase inhibitor combinations.
• Regulatory Incentives: Supportive initiatives such as the FDA’s QIDP designation and priority reviews are accelerating drug approvals in the infectious disease segment.
• Improved Diagnostic Technologies: Rapid molecular diagnostic tools are enabling quicker pathogen identification and targeted therapy, enhancing treatment outcomes.

Complicated Urinary Tract Infection Market Barriers

• High Cost of Novel cUTI Therapies: The premium pricing of newly approved antibiotics limits accessibility, especially in low- and middle-income countries.
• Limited cUTI Pipeline Diversity: Despite innovation, the number of truly novel antibiotic mechanisms remains limited, restricting long-term treatment options.
• Antibiotic Stewardship Challenges: Strict usage regulations to prevent resistance development may reduce overall market uptake of new antibiotics.
• Rising Resistance Even to New Drugs: Emerging resistance to recently launched treatments threatens market sustainability and effectiveness.
• Low Awareness and Delayed Diagnosis: Lack of early detection and public awareness, especially in developing regions, hampers timely treatment and market penetration.

Scope of the Complicated Urinary Tract Infection Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Complicated Urinary Tract Infection Companies: Merck Sharp & Dohme, AbbVie, Pfizer, Allecra Therapeutics, Wockhardt, Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, GlaxoSmithKline, Locus Biosciences, Forest Laboratories, Allecra, Xiangbei Welman Pharmaceutical, Bayer, Mepha Ltd., Pinnacle Pharmaceuticals, Inc., Bionorica SE, and others
• Key Complicated Urinary Tract Infection Therapies: RECARBRIO (imipenem, cilastatin, and relebactam), AVYCAZ (ceftazidime/avibactam), enmetazobactam, zidebactam (WCK-5222), Tebipenem Pivoxil Hydrobromide (SPR994), Cefepime/zidebactam (WCK-5222), Cefepime/taniborbactam, Gepotidacin, LBP-EC01, Ceftaroline fosamil and NXL104 (q8h), cefepime/AAI101 combination, Piperacillin Sodium and Sulbactam Sodium, Cipro XR (Ciprofloxacin, BAYQ3939), Nitrofurantoin, PP4001, Canephron® N, and others
• Complicated Urinary Tract Infection Therapeutic Assessment: Complicated Urinary Tract Infection current marketed and Complicated Urinary Tract Infection emerging therapies
• Complicated Urinary Tract Infection Market Dynamics: Complicated Urinary Tract Infection market drivers and Complicated Urinary Tract Infection market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Complicated Urinary Tract Infection Unmet Needs, KOL’s views, Analyst’s views, Complicated Urinary Tract Infection Market Access and Reimbursement

To know more about Complicated Urinary Tract Infection companies working in the treatment market, visit @ Complicated Urinary Tract Infection Clinical Trials and Therapeutic Assessment